JP2018528783A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528783A5 JP2018528783A5 JP2018515456A JP2018515456A JP2018528783A5 JP 2018528783 A5 JP2018528783 A5 JP 2018528783A5 JP 2018515456 A JP2018515456 A JP 2018515456A JP 2018515456 A JP2018515456 A JP 2018515456A JP 2018528783 A5 JP2018528783 A5 JP 2018528783A5
- Authority
- JP
- Japan
- Prior art keywords
- duplex
- modified
- modified oligonucleotide
- extrahepatic
- section
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 212
- 239000002777 nucleoside Substances 0.000 claims description 172
- 102000039446 nucleic acids Human genes 0.000 claims description 148
- 108020004707 nucleic acids Proteins 0.000 claims description 148
- 150000007523 nucleic acids Chemical class 0.000 claims description 148
- 125000003835 nucleoside group Chemical group 0.000 claims description 100
- 150000001875 compounds Chemical class 0.000 claims description 77
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 60
- 210000004185 liver Anatomy 0.000 claims description 17
- 125000002619 bicyclic group Chemical group 0.000 claims description 16
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 13
- 150000004713 phosphodiesters Chemical class 0.000 claims description 12
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 claims description 5
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 5
- 210000002460 smooth muscle Anatomy 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 56
- 210000004027 cell Anatomy 0.000 description 48
- 230000000692 anti-sense effect Effects 0.000 description 37
- -1 TNF- [alpha] Proteins 0.000 description 35
- 230000000694 effects Effects 0.000 description 32
- 125000005647 linker group Chemical group 0.000 description 32
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 102100032187 Androgen receptor Human genes 0.000 description 16
- 108010080146 androgen receptors Proteins 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- 102100038369 1-acyl-sn-glycerol-3-phosphate acyltransferase beta Human genes 0.000 description 8
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 8
- 108091010877 Allograft inflammatory factor 1 Proteins 0.000 description 8
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 8
- 102100030461 Alpha-ketoglutarate-dependent dioxygenase FTO Human genes 0.000 description 8
- 102100034594 Angiopoietin-1 Human genes 0.000 description 8
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 description 8
- 102100022802 BTB/POZ domain-containing protein KCTD15 Human genes 0.000 description 8
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 8
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 8
- 102100023073 Calcium-activated potassium channel subunit alpha-1 Human genes 0.000 description 8
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 8
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 8
- 101710101477 Carbohydrate-responsive element-binding protein Proteins 0.000 description 8
- 102100037403 Carbohydrate-responsive element-binding protein Human genes 0.000 description 8
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 8
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 8
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 8
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 8
- 102100035762 Diacylglycerol O-acyltransferase 2 Human genes 0.000 description 8
- 102100039577 ETS translocation variant 5 Human genes 0.000 description 8
- 108010074864 Factor XI Proteins 0.000 description 8
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 8
- 102100040890 Glucagon receptor Human genes 0.000 description 8
- 102100036702 Glucosamine-6-phosphate isomerase 2 Human genes 0.000 description 8
- 102100020948 Growth hormone receptor Human genes 0.000 description 8
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 8
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 8
- 101000605571 Homo sapiens 1-acyl-sn-glycerol-3-phosphate acyltransferase beta Proteins 0.000 description 8
- 101001062620 Homo sapiens Alpha-ketoglutarate-dependent dioxygenase FTO Proteins 0.000 description 8
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 8
- 101000693085 Homo sapiens Angiopoietin-related protein 3 Proteins 0.000 description 8
- 101000974798 Homo sapiens BTB/POZ domain-containing protein KCTD15 Proteins 0.000 description 8
- 101001049859 Homo sapiens Calcium-activated potassium channel subunit alpha-1 Proteins 0.000 description 8
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 8
- 101000930020 Homo sapiens Diacylglycerol O-acyltransferase 2 Proteins 0.000 description 8
- 101000813745 Homo sapiens ETS translocation variant 5 Proteins 0.000 description 8
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 8
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 description 8
- 101001072480 Homo sapiens Glucosamine-6-phosphate isomerase 2 Proteins 0.000 description 8
- 101001075287 Homo sapiens Growth hormone receptor Proteins 0.000 description 8
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 8
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 8
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 8
- 101000604641 Homo sapiens Katanin p60 ATPase-containing subunit A1 Proteins 0.000 description 8
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 description 8
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 8
- 101001013994 Homo sapiens Mitochondrial carrier homolog 2 Proteins 0.000 description 8
- 101001013832 Homo sapiens Mitochondrial peptide methionine sulfoxide reductase Proteins 0.000 description 8
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 8
- 101000969961 Homo sapiens Neurexin-3 Proteins 0.000 description 8
- 101000969963 Homo sapiens Neurexin-3-beta Proteins 0.000 description 8
- 101000973623 Homo sapiens Neuronal growth regulator 1 Proteins 0.000 description 8
- 101000603202 Homo sapiens Nicotinamide N-methyltransferase Proteins 0.000 description 8
- 101000602930 Homo sapiens Nuclear receptor coactivator 2 Proteins 0.000 description 8
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 8
- 101000981737 Homo sapiens Protein lifeguard 2 Proteins 0.000 description 8
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 8
- 101000707152 Homo sapiens SH2B adapter protein 1 Proteins 0.000 description 8
- 101000898985 Homo sapiens Seipin Proteins 0.000 description 8
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 8
- 101000891620 Homo sapiens TBC1 domain family member 1 Proteins 0.000 description 8
- 101000962461 Homo sapiens Transcription factor Maf Proteins 0.000 description 8
- 101000597758 Homo sapiens Transmembrane protein 18 Proteins 0.000 description 8
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 8
- 102100038197 Katanin p60 ATPase-containing subunit A1 Human genes 0.000 description 8
- 102000016267 Leptin Human genes 0.000 description 8
- 108010092277 Leptin Proteins 0.000 description 8
- 102100023724 Melanocortin receptor 4 Human genes 0.000 description 8
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 8
- 102100031332 Mitochondrial carrier homolog 2 Human genes 0.000 description 8
- 102100031767 Mitochondrial peptide methionine sulfoxide reductase Human genes 0.000 description 8
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 8
- 102100021310 Neurexin-3 Human genes 0.000 description 8
- 102100022223 Neuronal growth regulator 1 Human genes 0.000 description 8
- 102100038951 Nicotinamide N-methyltransferase Human genes 0.000 description 8
- 108010062309 Nuclear Receptor Interacting Protein 1 Proteins 0.000 description 8
- 102100037226 Nuclear receptor coactivator 2 Human genes 0.000 description 8
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 8
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 8
- 102100029558 Nuclear receptor-interacting protein 1 Human genes 0.000 description 8
- 108010016731 PPAR gamma Proteins 0.000 description 8
- 102000017795 Perilipin-1 Human genes 0.000 description 8
- 108010067162 Perilipin-1 Proteins 0.000 description 8
- 102000017794 Perilipin-2 Human genes 0.000 description 8
- 108010067163 Perilipin-2 Proteins 0.000 description 8
- 102000001486 Perilipin-3 Human genes 0.000 description 8
- 108010068633 Perilipin-3 Proteins 0.000 description 8
- 102000001487 Perilipin-4 Human genes 0.000 description 8
- 108010068636 Perilipin-4 Proteins 0.000 description 8
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 8
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 8
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 8
- 102100026531 Prelamin-A/C Human genes 0.000 description 8
- 102100024135 Protein lifeguard 2 Human genes 0.000 description 8
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 8
- 101000613608 Rattus norvegicus Monocyte to macrophage differentiation factor Proteins 0.000 description 8
- 102000007156 Resistin Human genes 0.000 description 8
- 108010047909 Resistin Proteins 0.000 description 8
- 102100031770 SH2B adapter protein 1 Human genes 0.000 description 8
- 108091006587 SLC13A5 Proteins 0.000 description 8
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 8
- 102100021463 Seipin Human genes 0.000 description 8
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 8
- 102100035210 Solute carrier family 13 member 5 Human genes 0.000 description 8
- 102100040238 TBC1 domain family member 1 Human genes 0.000 description 8
- 101150050957 TNKS gene Proteins 0.000 description 8
- 102000003567 TRPV4 Human genes 0.000 description 8
- 101150098315 TRPV4 gene Proteins 0.000 description 8
- 102000004893 Transcription factor AP-2 Human genes 0.000 description 8
- 108090001039 Transcription factor AP-2 Proteins 0.000 description 8
- 102100039189 Transcription factor Maf Human genes 0.000 description 8
- 102100035318 Transmembrane protein 18 Human genes 0.000 description 8
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 8
- 229940039781 leptin Drugs 0.000 description 8
- 102000005861 leptin receptors Human genes 0.000 description 8
- 108010019813 leptin receptors Proteins 0.000 description 8
- NJHLGKJQFKUSEA-UHFFFAOYSA-N n-[2-(4-hydroxyphenyl)ethyl]-n-methylnitrous amide Chemical compound O=NN(C)CCC1=CC=C(O)C=C1 NJHLGKJQFKUSEA-UHFFFAOYSA-N 0.000 description 8
- 235000021092 sugar substitutes Nutrition 0.000 description 8
- 239000003765 sweetening agent Substances 0.000 description 8
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000005153 frontal cortex Anatomy 0.000 description 6
- 210000003497 sciatic nerve Anatomy 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 210000003594 spinal ganglia Anatomy 0.000 description 6
- 210000000427 trigeminal ganglion Anatomy 0.000 description 6
- 208000003098 Ganglion Cysts Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000005400 Synovial Cyst Diseases 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102100034608 Angiopoietin-2 Human genes 0.000 description 4
- 102000049320 CD36 Human genes 0.000 description 4
- 108010045374 CD36 Antigens Proteins 0.000 description 4
- 101150013553 CD40 gene Proteins 0.000 description 4
- 102100021158 Double homeobox protein 4 Human genes 0.000 description 4
- 108010044191 Dynamin II Proteins 0.000 description 4
- 102100021238 Dynamin-2 Human genes 0.000 description 4
- 102100024108 Dystrophin Human genes 0.000 description 4
- 102100022447 Eukaryotic translation initiation factor 4E-binding protein 2 Human genes 0.000 description 4
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 4
- 101000968549 Homo sapiens Double homeobox protein 4 Proteins 0.000 description 4
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 description 4
- 101000678283 Homo sapiens Eukaryotic translation initiation factor 4E-binding protein 2 Proteins 0.000 description 4
- 101001129187 Homo sapiens Patatin-like phospholipase domain-containing protein 2 Proteins 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 4
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 4
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 4
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 4
- 108091006269 SLC5A2 Proteins 0.000 description 4
- 101001053942 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Diphosphomevalonate decarboxylase Proteins 0.000 description 4
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 description 4
- 208000026062 Tissue disease Diseases 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 210000000593 adipose tissue white Anatomy 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 210000001593 brown adipocyte Anatomy 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 4
- 201000006938 muscular dystrophy Diseases 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 210000003635 pituitary gland Anatomy 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 210000000636 white adipocyte Anatomy 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical group OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 208000000943 scapulohumeral muscular dystrophy Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562233292P | 2015-09-25 | 2015-09-25 | |
| US62/233,292 | 2015-09-25 | ||
| PCT/US2016/053836 WO2017053999A1 (en) | 2015-09-25 | 2016-09-26 | Conjugated antisense compounds and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018528783A JP2018528783A (ja) | 2018-10-04 |
| JP2018528783A5 true JP2018528783A5 (enExample) | 2019-11-07 |
Family
ID=58387451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515456A Pending JP2018528783A (ja) | 2015-09-25 | 2016-09-26 | コンジュゲートアンチセンス化合物及びその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11116843B2 (enExample) |
| EP (1) | EP3353306A4 (enExample) |
| JP (1) | JP2018528783A (enExample) |
| WO (1) | WO2017053999A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11433089B2 (en) | 2016-09-23 | 2022-09-06 | National University Corporation Tokyo Medical And Dental University | Blood-brain barrier permeable heteroduplex nucleic acid |
| KR102850887B1 (ko) | 2017-08-03 | 2025-08-28 | 보이저 테라퓨틱스, 인크. | Aav의 전달을 위한 조성물 및 방법 |
| CA3099522C (en) * | 2017-09-19 | 2024-10-08 | The Governors Of The University Of Alberta | GAPMERES AND METHODS OF USING THESE FOR THE TREATMENT OF MUSCULAR DYSTROPHY |
| EP4257691A3 (en) | 2017-12-14 | 2024-01-10 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| MY203356A (en) | 2018-01-12 | 2024-06-25 | Bristol Myers Squibb Co | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| JP7547201B2 (ja) | 2018-01-12 | 2024-09-09 | ブリストル－マイヤーズ スクイブ カンパニー | アルファ－シヌクレインを標的とするアンチセンスオリゴヌクレオチドおよびその使用 |
| CN112020559A (zh) | 2018-02-21 | 2020-12-01 | 百时美施贵宝公司 | Camk2d反义寡核苷酸及其用途 |
| US11597928B2 (en) | 2018-03-14 | 2023-03-07 | National University Corporation Tokyo Medical And Dental University | Nucleic acid complex |
| WO2019182294A1 (ko) * | 2018-03-19 | 2019-09-26 | 주식회사 케이티 | 비디오 신호 처리 방법 및 장치 |
| JP7333079B2 (ja) | 2018-03-19 | 2023-08-24 | 国立大学法人 東京医科歯科大学 | 毒性が軽減した核酸 |
| WO2019182109A1 (ja) | 2018-03-22 | 2019-09-26 | 国立大学法人東京医科歯科大学 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
| WO2020072991A1 (en) * | 2018-10-05 | 2020-04-09 | Ionis Pharmaceuticals, Inc. | Modified oligomeric compounds and uses thereof |
| JP7667074B2 (ja) * | 2019-03-29 | 2025-04-22 | 田辺三菱製薬株式会社 | Ｄｕｘ４の発現を調節するための化合物、方法及び医薬組成物 |
| CN113677374A (zh) * | 2019-04-08 | 2021-11-19 | 国立大学法人东京医科齿科大学 | 肌疾病治疗用药物组合物 |
| EP4032551A4 (en) * | 2019-09-18 | 2023-12-20 | National University Corporation Tokyo Medical and Dental University | NUCLEIC ACID COMPLEX |
| EP4043565A4 (en) * | 2019-10-11 | 2024-01-24 | National University Corporation Tokyo Medical and Dental University | MODIFIED HETERONUCLEIC ACID |
| CA3160329A1 (en) * | 2019-11-06 | 2021-05-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| IL294479A (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CA3192884A1 (en) * | 2020-09-04 | 2022-03-10 | The University Of Chicago | Nucleic acid-derivatized therapeutics |
| CN120384079A (zh) * | 2020-09-30 | 2025-07-29 | 亿腾医药（苏州）有限公司 | 血管生成素样3的siRNA及其用途 |
| CA3202708A1 (en) | 2020-11-23 | 2022-05-27 | Alpha Anomeric Sas | Nucleic acid duplexes |
| AR124713A1 (es) * | 2021-01-28 | 2023-04-26 | Dicerna Pharmaceuticals Inc | Composiciones y métodos para inhibir la expresión de genes en el sistema nervioso central |
| TW202400787A (zh) | 2022-03-16 | 2024-01-01 | 美商安彼瑞可股份有限公司 | 改良siRNA生物可利用性之GalNAc組合物 |
| US12258563B2 (en) | 2022-03-28 | 2025-03-25 | Empirico Inc. | Modified oligonucleotides |
| JP2025516680A (ja) | 2022-05-13 | 2025-05-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 一本鎖ループオリゴヌクレオチド |
| WO2024238385A2 (en) | 2023-05-12 | 2024-11-21 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
| TW202508607A (zh) * | 2023-05-19 | 2025-03-01 | 大陸商北京炫景瑞醫藥科技有限公司 | 雙股寡核苷酸及其共軛物和用途 |
| WO2024257861A1 (ja) * | 2023-06-16 | 2024-12-19 | 日産化学株式会社 | 脂質結合オリゴヌクレオチド又はその複合体 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833992B2 (en) * | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US20070105803A1 (en) | 2005-08-18 | 2007-05-10 | Muthiah Manoharan | Methods and compositions for treating neurological disease |
| EP2231194B1 (en) * | 2007-12-04 | 2017-02-22 | Alnylam Pharmaceuticals Inc. | Folate-irna conjugates |
| US20100048676A1 (en) * | 2008-08-04 | 2010-02-25 | University Of Rochester | Non-androgen dependent roles for androgen receptor in liver cancer |
| US20100222417A1 (en) * | 2008-11-26 | 2010-09-02 | Alnylam Pharmaceuticals | Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues |
| EP2396038B1 (en) * | 2009-02-12 | 2015-10-21 | CuRNA, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| EP3031920B1 (en) | 2010-07-19 | 2019-08-21 | Ionis Pharmaceuticals, Inc. | Modulation of dystrophia myotonica-protein kinase (dmpk) expression |
| CA2848753C (en) * | 2011-09-14 | 2022-07-26 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
| CN104126010B (zh) | 2011-12-16 | 2021-04-06 | 国立大学法人东京医科齿科大学 | 嵌合的双链核酸 |
| US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| EP2961841B1 (en) | 2013-03-01 | 2020-01-22 | National University Corporation Tokyo Medical and Dental University | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent |
| DK2991656T3 (da) | 2013-05-01 | 2020-03-23 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression |
| CA2913499A1 (en) | 2013-05-30 | 2014-12-04 | National University Corporation Tokyo Medical And Dental University | Double-stranded agents for delivering therapeutic oligonucleotides |
| CN105324119A (zh) | 2013-06-16 | 2016-02-10 | 国立大学法人东京医科齿科大学 | 具有外显子跳跃效应的双链反义核酸 |
| TW201536329A (zh) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| WO2015183943A2 (en) * | 2014-05-27 | 2015-12-03 | Trustees Of Boston University | Inhibitors of fibroproliferative disorders and cancer |
| EP3180426B1 (en) * | 2014-08-17 | 2019-12-25 | The Broad Institute, Inc. | Genome editing using cas9 nickases |
| US20210052631A1 (en) | 2015-09-25 | 2021-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
-
2016
- 2016-09-26 EP EP16849895.4A patent/EP3353306A4/en not_active Withdrawn
- 2016-09-26 US US15/761,786 patent/US11116843B2/en active Active
- 2016-09-26 WO PCT/US2016/053836 patent/WO2017053999A1/en not_active Ceased
- 2016-09-26 JP JP2018515456A patent/JP2018528783A/ja active Pending
-
2021
- 2021-08-10 US US17/398,490 patent/US20220023429A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528783A5 (enExample) | ||
| US11116843B2 (en) | Conjugated antisense compounds and their use | |
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| JP5763539B2 (ja) | ５’及び２’ビス置換ヌクレオシド及びそれから製造されるオリゴマー化合物 | |
| US9428750B2 (en) | Oligomeric compounds comprising tricyclic nucleosides and methods for their use | |
| RU2015151199A (ru) | Сопряженные антисмысловые соединения и их применение | |
| JP2021072862A (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| US20160186175A1 (en) | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom | |
| US9249178B2 (en) | Tricyclic nucleosides and oligomeric compounds prepared therefrom | |
| KR20200104347A (ko) | 포스포로디티오에이트 인터뉴클레오시드 연결을 포함하는 갭머 올리고뉴클레오티드 | |
| EP3516062A1 (en) | Myostatin irna compositions and methods of use thereof | |
| US20250263703A1 (en) | Linkage Modified Oligomeric Compounds | |
| US20160186174A1 (en) | Substituted morpholino compounds analogs thereof and oligomeric compounds prepared therefrom | |
| JPWO2021030213A5 (enExample) | ||
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| US20220098595A1 (en) | Nr2e3 expression reducing oligonucleotides, compositions containing the same, and methods of their use | |
| JP6934695B2 (ja) | 核酸医薬とその使用 | |
| WO2022266486A2 (en) | Products and compositions | |
| CN117813383B (zh) | 用于抑制CIDEB基因表达的siRNA、药物及其应用 | |
| EP3914713A1 (en) | Nrl expression reducing oligonucleotides, compositions containing the same, and methods of their use | |
| US20250368998A1 (en) | Nucleotide analogues, and preparation and application thereof | |
| JP7813254B2 (ja) | Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド | |
| WO2020044349A1 (en) | Compounds, cojugates and compositions for use in the methods for trans-membrane delivery of molecules | |
| WO2026009916A1 (ja) | ２本鎖オリゴヌクレオチド | |
| DE102022124232A1 (de) | Antisense-Oligonukleotide für die Behandlung des Joubert-Syndroms |